Neoadjuvant Chemotherapy for Patients With Diaphragmatic Lesions: A Prognostic Postoperative Analysis

We aimed to analyse the prognosis of patients who underwent primary debulking surgery (PDS) and those who underwent interval debulking surgery (IDS) following four courses of paclitaxel+ carboplatin as preoperative chemotherapy to examine the usefulness of preoperative chemotherapy. We included 45 p...

Full description

Saved in:
Bibliographic Details
Published in:In vivo (Athens) 2020-05, Vol.34 (3), p.1277-1281
Main Authors: Saito, Motoaki, Odajima, Suguru, Ezawa, Masahiro, Iida, Yasushi, Ueda, Kazu, Yanaihara, Nozomu, Tanabe, Hiroshi, Takano, Hirokuni, Yamada, Kyosuke, Okamoto, Aikou
Format: Article
Language:English
Subjects:
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Chemotherapy, Adjuvant
Diaphragm - pathology
Female
Humans
Kaplan-Meier Estimate
Middle Aged
Neoadjuvant Therapy
Neoplasm Grading
Neoplasm Staging
Ovarian Neoplasms - pathology
Peritoneal Neoplasms - diagnosis
Peritoneal Neoplasms - drug therapy
Peritoneal Neoplasms - secondary
Postoperative Care
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We aimed to analyse the prognosis of patients who underwent primary debulking surgery (PDS) and those who underwent interval debulking surgery (IDS) following four courses of paclitaxel+ carboplatin as preoperative chemotherapy to examine the usefulness of preoperative chemotherapy. We included 45 patients with epithelial ovarian and peritoneal cancers accompanied with diaphragmatic lesions who underwent standard surgery combined with diaphragmatic surgery at two related institutions in January 2010-December 2013. Using medical records, we surveyed the recurrence period, recurrence site, and date of last confirmed survival, and analysed prognosis. The PDS and IDS groups comprised 32 and 13 patients (overall survival, 61.2 and 43.2 months), respectively. Progression-free survival in the PDS and IDS groups was 31.2 and 16.8 months, respectively. NAC-IDS can be a standard treatment option for patients with a tumour in the triangular ligament, in whom complete surgery is difficult.
ISSN:0258-851X
1791-7549
DOI:10.21873/invivo.11902